[1]金彩英.孟鲁司特钠治疗儿童呼吸道合胞病毒感染毛细支气管炎的效果及其对炎症因子的影响[J].医学信息,2022,35(01):162-164.[doi:10.3969/j.issn.1006-1959.2022.01.040]
　JIN Cai-ying.Effect of Montelukast Sodium on Bronchiolitis Caused by Respiratory Syncytial Virus Infection in Children and its Effect on Inflammatory Factors[J].Medical Information,2022,35(01):162-164.[doi:10.3969/j.issn.1006-1959.2022.01.040]
点击复制

孟鲁司特钠治疗儿童呼吸道合胞病毒感染毛细支气管炎的效果及其对炎症因子的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年01期
页码:
162-164
栏目:
药物与临床
出版日期:
2022-01-01

文章信息/Info

Title:
Effect of Montelukast Sodium on Bronchiolitis Caused by Respiratory Syncytial Virus Infection in Children and its Effect on Inflammatory Factors
文章编号:
1006-1959（2022）01-0162-03
作者:
金彩英
（东港市中心医院儿科，辽宁 东港 118300）
Author(s):
JIN Cai-ying
(Department of Pediatrics,Donggang Central Hospital,Donggang 118300,Liaoning,China)
关键词:
呼吸道合胞病毒感染; 毛细支气管炎; 孟鲁司特钠; 炎症因子
Keywords:
Respiratory syncytial virus infection; Bronchiolitis; Montelukast sodium; Inflammatory factors
分类号:
R187.3
DOI:
10.3969/j.issn.1006-1959.2022.01.040
文献标志码:
A
摘要:
目的 研究采用孟鲁司特钠治疗儿童呼吸道合胞病毒感染毛细支气管炎的疗效及对炎症因子的影响。方法 选取2020年5月-2021年5月在我院诊治的104例呼吸道合胞病毒感染毛细支气管炎儿童为研究对象，采用随机数字表法分为对照组和观察组，各52例。对照组给予布地奈德雾化吸入治疗，观察组在对照组基础上给予孟鲁司特钠治疗，比较两组临床治疗总有效率、临床症状消失时间、炎症因子水平[血清嗜酸粒细胞阳离子蛋白（ECP）、白细胞介素-4（IL-4）、白细胞介素-8（IL-8）、肿瘤坏死因子-α（TNF-α）]、不良反应以及复发率。结果 观察组治疗总有效率为90.38%，高于对照组的80.77%（P＜0.05）；观察组咳嗽、憋喘、呼吸困难、肺部啰音消失时间均短于对照组（P＜0.05）；两组ECP、IL-4、IL-8、TNF-α水平均低于治疗前，且观察组低于对照组（P＜0.05）；观察组不良反应发生率为3.85%，与对照组的5.77%比较，差异无统计学意义（P＞0.05）；随访2个月，观察组复发率为7.69%，低于对照组的17.31%（P＜0.05）。结论 采用孟鲁司特钠治疗儿童呼吸道合胞病毒感染毛细支气管炎效果确切，治疗总有效率高，症状改善显著，炎症因子水平下降显著，复发率低，且不会增加不良反应，是一种安全、有效的临床治疗药物。
Abstract:
Objective To study the clinical efficacy of montelukast sodium in the treatment of children with human respiratory syncytial virus infection and its effect on inflammatory factors.Methods A total of 104 children with bronchiolitis infected by respiratory syncytial virus who were diagnosed and treated in our hospital from May 2020 to May 2021 were selected as the research objects. They were divided into control group and observation group by random number table, with 52 cases in each group. The control group was treated with budesonide inhalation, and the observation group was treated with montelukast sodium on the basis of the control group. The total effective rate of clinical treatment, the disappearance time of clinical symptoms, the levels of inflammatory factors [serum eosinophil cationic protein (ECP), interleukin-4 (IL-4), interleukin-8 (IL-8), tumor necrosis factor-α (TNF-α)], adverse reactions and recurrence rate were compared between the two groups.Results The total effective rate in the observation group was 90.38%, which was higher than 80.77% in the control group (P<0.05). The disappearance time of cough, asthma, dyspnea and pulmonary rales in the observation group was shorter than that in the control group (P<0.05). After treatment, ECP, IL-4, IL-8 and TNF-α levels in both groups were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05). The incidence of adverse reactions in the observation group was 3.85%, which was compared with 5.77% in the control group, the difference was not statistically significant (P>0.05). After two months of follow-up, the recurrence rate in the observation group was 7.69%, which was lower than 17.31% in the control group (P<0.05).Conclusion Montelukast sodium is effective in the treatment of children with human respiratory syncytial virus bronchiolitis infection, the total effective rate is high, the symptoms are improved significantly, the levels of inflammatory factors are decreased significantly, the recurrence rate is low, and the adverse reactions are not increased. It is a safe and effective clinical treatment drug.

参考文献/References:

[1]刘敏宁,高阳,张雪平.孟鲁司特钠治疗儿童呼吸道合胞病毒感染毛细支气管炎的疗效及其对炎症因子的影响[J].儿科药学杂志,2019,25(8):22-24.[2]刘雪茹,胡艳,陈和斌,等.孟鲁司特钠治疗儿童呼吸道合胞病毒感染毛细支气管炎的疗效及对炎症标志物的影响[J].中华医院感染学杂志,2018,28(2):276-279.[3]姚强.喘可治雾化吸入辅助治疗婴幼儿呼吸道合胞病毒毛细支气管炎的临床效果[J].中国医药导报,2018,15(18):72-75,91.[4]House SA,Ralston SL.Diagnosis, prevention, and management of bronchiolitis in children: review of current controversies[J].Minerva Pediatr,2017,69(2):141-155.[5]牛庆玲,李晶,韩秋果.布地奈德联合孟鲁司特钠治疗毛细支气管炎哮喘发作[J].齐齐哈尔医学院学报,2018,39(14):1661-1662.[6]《中华儿科杂志》编辑委员会,中华医学会儿科学分会呼吸学组.毛细支气管炎诊断、治疗与预防专家共识[J].中华儿科杂志,2015(53):168-171.[7]刘调侠,李延琴.孟鲁司特钠联合布地奈德治疗小儿毛细支气管炎的临床疗效及其对炎症因子的影响[J].儿科药学杂志,2017,23(6):27-30.[8]孙丹萌.氨溴特罗联合孟鲁司特钠咀嚼片治疗儿童毛细支气管炎的疗效及对免疫学指标的影响[J].实用临床医药杂志,2018,22(7):89-92.[9]沈杨,罗菲菲,王亚亭,等.孟鲁司特钠联合维生素D辅助治疗呼吸道合胞病毒毛细支气管炎的疗效观察[J].安徽医科大学学报,2018,53(2):297-300.[10]夏小兰,马露,崔倪.孟鲁司特钠治疗小儿呼吸道合胞病毒感染毛细支气管炎的疗效及对血清CysLTs、ECP水平的影响[J].中国医学前沿杂志,2018,10(11):24-27.[11]陈赛男,王宇清,郝创利,等.儿童毛细支气管炎后反复喘息的发生情况及危险因素分析[J].中华实用儿科临床杂志,2019,34(9):660-664.[12]Ho SW,Huang KY,Teng YH,et al.Practice Variations between Emergency Physicians and Pediatricians in Treating Acute Bronchiolitis in the Emergency Department: A Nationwide Study[J].J Emerg Med,2015,48(5):536-541.[13]邓宇红,李莉.孟鲁司特钠治疗儿童呼吸道合胞病毒毛细支气管炎的临床评价[J].药物评价研究,2016(6):664-667.[14]杨洋,郭悦鹏,袁晓梅,等.孟鲁司特对支气管哮喘大鼠辅助性T细胞17/调节性Ｔ细胞平衡的影响及意义[J].新乡医学院学报,2016(1):24-27.[15]何月贤,宋文秀,张丽梅,等.呼吸道合胞病毒感染致毛细支气管炎患儿血清TLR4、TGF-β1水平变化观察[J].山东医药,2020,60(12):65-68.[16]周娟娟,杨俊梅,高凯杰,等.2018年河南省儿童医院细菌耐药性监测[J].中国感染与化疗杂志,2020,20(2):202-208.[17]孙永烽,杨勤,陈敏,等.198例小儿重症肺炎病原学分析[J].贵州医科大学学报报,2020,45(3):345-349,355.[18]郑春茂,陈碧,谭志美.美罗培南的药动学/药效学趋向关系及其增效的选择适宜性[J].中国药业,2020,29(12):41-45.[19]陈洋洋.孟鲁司特钠联合干扰素α-2b对呼吸道合胞病毒感染毛细支气管炎患儿血清炎性因子水平及康复进程的影响[J].中国中西医结合儿科学,2020,12(2):164-167.[20]刘丹,田钟元,徐帅.对症基础治疗联合孟鲁司特钠治疗儿童呼吸道合胞病毒感染毛细支气管炎的疗效及预后观察[J].哈尔滨医药,2020,40(6):2.

更新日期/Last Update: 1900-01-01